Perek N, Denoyer D, Dubois F, Koumanov F
Department of Biophysics and Image Treatment-Cell death and neoplasia group, Faculty of Medicine Jacques Lisfranc, Saint-Etienne cedex 02, France.
Gen Physiol Biophys. 2002 Dec;21(4):381-404.
Two radiopharmaceuticals, Tc-99m-MIBI (MIBI) and Tc-99m-Tetrofosmin (Tfos), are currently used for in vivo non-invasive monitoring of the MultiDrug Resistant (MDR) status of tumours. As gliomas are highly multidrug resistant, it is expected that the tracers would be poorly retained in those cells, but the in vivo and in vitro studies to date have shown that Tfos was highly retained in malignant gliomas. The high degree of malignancy of tumour cells is linked to alterations of physiological parameters as plasma membrane potential and intracellular pH. In order to elucidate the contribution of those parameters to Tfos and MIBI uptakes in malignant gliomas, we used several glioma cell lines--G111, G5, G152, and 42 MG-BA. These cells showed to be chemoresistant with a high level of expression and activity of the Multidrug Resistant associated Protein 1 (MRP1). They also had an alkaline intracellular pH (pHi) related to the Na+/H+ antiporter (NHE-1) expression and depolarised plasma membranes (-45 to -55 mV). In spite of their chemoresistance, we have found a high accumulation of both radiotracers in gliomas, more important for Tfos than MIBI, related to the presence and activity of NHE-1. In conjunction, the uptakes of the tracers were only partially dependent upon the plasma membrane potential of the glioma cell lines, again Tfos uptake being less dependent on this parameter than MIBI uptake. In conclusion, the evidence accumulated in this study suggests that Tfos could be a suitable glioma marker in vivo.
目前有两种放射性药物,锝-99m-甲氧基异丁基异腈(MIBI)和锝-99m-替曲膦(Tfos),用于体内非侵入性监测肿瘤的多药耐药(MDR)状态。由于胶质瘤具有高度多药耐药性,预计这些示踪剂在这些细胞中的保留率会很低,但迄今为止的体内和体外研究表明,Tfos在恶性胶质瘤中高度保留。肿瘤细胞的高度恶性与生理参数如质膜电位和细胞内pH值的改变有关。为了阐明这些参数对恶性胶质瘤中Tfos和MIBI摄取的贡献,我们使用了几种胶质瘤细胞系——G111、G5、G152和42 MG-BA。这些细胞表现出对化疗耐药,多药耐药相关蛋白1(MRP1)的表达和活性水平较高。它们还具有与钠/氢反向转运体(NHE-1)表达相关的碱性细胞内pH值(pHi)和去极化的质膜(-45至-55 mV)。尽管它们具有化疗耐药性,但我们发现两种放射性示踪剂在胶质瘤中都有高度积累,对Tfos来说比对MIBI更重要,这与NHE-1的存在和活性有关。同时,示踪剂的摄取仅部分依赖于胶质瘤细胞系的质膜电位,同样,Tfos摄取比MIBI摄取对该参数的依赖性更小。总之,本研究积累的证据表明,Tfos可能是一种合适的体内胶质瘤标志物。